Overview and Scope
The COVID-19 saliva screening test potential refers to the potential advantages and capabilities that saliva-based tests for detecting SARS-CoV-2, the virus that causes COVID-19, could offer compared to traditional methods such as nasopharyngeal or oropharyngeal swab tests. Their potential lies in improving testing accessibility, patient acceptance, cost-effectiveness, and safety while enabling new testing strategies and approaches to manage the COVID-19 pandemic better.
Sizing and Forecast
The COVID-19 saliva screening test potential market size has grown strongly in recent years. It will grow from $3.57 billion in 2023 to $3.90 billion in 2024 at a compound annual growth rate (CAGR) of 9.3%. The growth in the historic period can be attributed to the potential for home testing, unprecedented need for diagnostic testing, rise in public awareness, and research and development investment.
The COVID-19 saliva screening test potential market size is expected to see strong growth in the next few years. It will grow to $5.64 billion in 2028 at a compound annual growth rate (CAGR) of 9.6%. The growth in the forecast period can be attributed to integration with screening programs, regulatory support, growing demand for speedy, point-of-care COVID-19 tests, increasing population, and the rise of e-commerce. Major trends in the forecast period include increased adoption in non-healthcare settings, integration with digital health platforms, emergence of next-generation technologies, technological advancements, and strategic partnerships.
Order your report now for swift delivery, visit the link:
https://www.thebusinessresearchcompany.com/report/covid-19-saliva-screening-test-potential-global-market-report
Segmentation & Regional Insights
The COVID-19 saliva screening test potential market covered in this report is segmented –
1) By Location: Travel Stations, Sports Arenas, Entertainment Venues, Corporate Campus Environments, Universities And Colleges, Factories, Other Locations
2) By Technology: Fluorescence-Labelled Antigen, RT-PCR, CRISPR-Cas9
3) By Mode of Testing: Centralized Testing, Decentralized Testing
North America was the largest region in the COVID-19 saliva screening test potential market in 2023. The regions covered in the COVID-19 saliva screening test potential market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Intrigued to explore the contents? Secure your hands-on a free sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=16026&type=smp
Major Driver Impacting Market Growth
The increasing healthcare expenditure is expected to propel the growth of the COVID-19 saliva screening test potential market going forward. Healthcare expenditure is the entire amount spent on healthcare-related goods and services, including prescription drugs, hospital stays, doctor visits, medical equipment, and public health campaigns. The healthcare expenditure is increasing due to several factors, such as minimally invasive surgeries, cutting-edge diagnostic tools, increase in research and development for new drugs, utilization of healthcare services, and specialty medications. The higher healthcare expenditure can provide the necessary resources and support to leverage the full potential of COVID-19 saliva screening tests, contributing to more effective pandemic management and better public health outcomes. For instance, in May 2023, according to the Office for National Statistics, a UK-based statistics authority, the UK’s healthcare expenditure grew by 9.7% in real terms and 9.4% in nominal terms. The overall amount spent on healthcare in the UK in 2021 was $367.25 billion (£280.7 billion), while the total amount spent on pharmaceuticals was $51.84 billion (£39.6 billion). Further, spending on preventative care more than quadrupled to $45.93 billion (£35.1 billion) in 2021 compared to the previous year. Therefore, the increasing healthcare expenditure is driving the growth of the COVID-19 saliva screening test potential market.
Key Industry Players
Major companies operating in the COVID-19 saliva screening test potential market are Roche Diagnostics Corporation, Thermo Fisher Scientific Inc., Abbott Laboratories, Becton Dickinson and Company, Danaher Corporation, University of North Carolina at Chapel Hill, Hologic Inc., Beaumont Health, PerkinElmer Inc., Quidel Corporation, University of Illinois at Urbana-Champaign, Cepheid, Seegene Inc., ARUP Laboratories, Vatic Health Limited, Ambry Genetics Corporation, LumiraDx Ltd., Yale School of Public Health, Gravity Diagnostics, Psomagen Inc., Fluidigm Corporation, Phosphorus Diagnostics LLC, DxTerity Diagnostics Inc., University of Notre Dame, MOgene, FLuroTech Ltd.
The covid-19 saliva screening test potential market report table of contents includes:
1. Executive Summary
- COVID-19 Saliva Screening Test Potential Market Characteristics
- COVID-19 Saliva Screening Test Potential Market Trends And Strategies
- COVID-19 Saliva Screening Test Potential Market – Macro Economic Scenario
- Global COVID-19 Saliva Screening Test Potential Market Size and Growth
.
- Global COVID-19 Saliva Screening Test Potential Market Competitive Benchmarking
- Global COVID-19 Saliva Screening Test Potential Market Competitive Dashboard
- Key Mergers And Acquisitions In The COVID-19 Saliva Screening Test Potential Market
- COVID-19 Saliva Screening Test Potential Market Future Outlook and Potential Analysis
- Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
